Quantitative Gel Zymography Reappraised for Matrix Metalloproteinases
|
By LabMedica International staff writers Posted on 29 Oct 2014 |

Image: The gel zymography separation of matrix metalloproteinases (MMPs) on a 7.5% polyacrylamide gel (Photo courtesy of the Italian National Research Council).
A reappraisal of quantitative gel zymography technique for matrix metalloproteinases (MMPs) in human plasma has been used for comparison with commercially available enzyme-linked immunosorbent assay (ELISA).
The determination of MMPs is relevant in numerous pathophysiological conditions, as imbalanced MMP activity is associated with many clinical conditions, including cardiovascular diseases, especially if associated with extracellular matrix remodeling, but the results obtained are closely linked to the method used and are not directly comparable.
Scientists at the Italian National Research Council (CNR; Pisa, Italy) obtained heparinized blood samples from 25 volunteers. The samples were centrifuged and the serum stored in aliquots at −80 °C. Gel zymography was performed based on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and on the use of gelatin 0.5% as substrate for detection of MMP enzymatic activity. Gelatinolytic activities were detected as unstained bands against the background of Coomassie Blue stained gelatin. In order to quantify the concentrations of the analyzed protein in the unknown samples, a dose-response curve was built in each run.
Total MMP-9 was measured in diluted plasma by specific immunometric assay (R&D Systems; Minneapolis, MN, USA), previously standardized. The working range was 0.19 ng/mL to 16 ng/mL, the sensitivity was 0.05 ± 0.01 ng/mL, and the within-assay variability was 414.3 ± 23.5 ng/mL (5.7%), while the between-assay variability was less than 15%. The concentration of total MMP-9 was measured in parallel using the zymography and ELISA for comparison purposes.
The results obtained by gel zymography analysis of human blood samples using different acrylamide/bis acrylamide ratios indicated that 7.5% gels are the more suitable for visualizing MMP-9 forms. In all conditions, four bands with gelatinolytic activity are found: MMP-9 dimers, MMP-9– tissue inhibitor of metalloproteinase1 (TIMP-1) complex, MMP-9, and MMP-2. The time course of the proteolytic activity of MMPs indicated 16 to 24 hours as optimal incubation time and these optimal parameters were used for routine assay. A linear positive correlation was found between the MMP-9 values of zymography and ELISA with the ELISA values significantly lower than those obtained with zymography.
The authors concluded that the main advantage of gel zymography is that it allows visualization of both the latent and active forms of gelatinases. The presence of MMP dimers and MMP/TIMP complexes in the plasma samples, revealed by gel zymography, could thoroughly characterize the role of MMP in associated diseases. Gel zymography allows separation and visualization of MMP-2 bands, so both MMP-2 and MMP-9 can be determined in the same run from a single biological sample. The study was published in the September 2014 issue of the Journal of Clinical Laboratory Analysis.
Related Links:
Italian National Research Council
R&D Systems
The determination of MMPs is relevant in numerous pathophysiological conditions, as imbalanced MMP activity is associated with many clinical conditions, including cardiovascular diseases, especially if associated with extracellular matrix remodeling, but the results obtained are closely linked to the method used and are not directly comparable.
Scientists at the Italian National Research Council (CNR; Pisa, Italy) obtained heparinized blood samples from 25 volunteers. The samples were centrifuged and the serum stored in aliquots at −80 °C. Gel zymography was performed based on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and on the use of gelatin 0.5% as substrate for detection of MMP enzymatic activity. Gelatinolytic activities were detected as unstained bands against the background of Coomassie Blue stained gelatin. In order to quantify the concentrations of the analyzed protein in the unknown samples, a dose-response curve was built in each run.
Total MMP-9 was measured in diluted plasma by specific immunometric assay (R&D Systems; Minneapolis, MN, USA), previously standardized. The working range was 0.19 ng/mL to 16 ng/mL, the sensitivity was 0.05 ± 0.01 ng/mL, and the within-assay variability was 414.3 ± 23.5 ng/mL (5.7%), while the between-assay variability was less than 15%. The concentration of total MMP-9 was measured in parallel using the zymography and ELISA for comparison purposes.
The results obtained by gel zymography analysis of human blood samples using different acrylamide/bis acrylamide ratios indicated that 7.5% gels are the more suitable for visualizing MMP-9 forms. In all conditions, four bands with gelatinolytic activity are found: MMP-9 dimers, MMP-9– tissue inhibitor of metalloproteinase1 (TIMP-1) complex, MMP-9, and MMP-2. The time course of the proteolytic activity of MMPs indicated 16 to 24 hours as optimal incubation time and these optimal parameters were used for routine assay. A linear positive correlation was found between the MMP-9 values of zymography and ELISA with the ELISA values significantly lower than those obtained with zymography.
The authors concluded that the main advantage of gel zymography is that it allows visualization of both the latent and active forms of gelatinases. The presence of MMP dimers and MMP/TIMP complexes in the plasma samples, revealed by gel zymography, could thoroughly characterize the role of MMP in associated diseases. Gel zymography allows separation and visualization of MMP-2 bands, so both MMP-2 and MMP-9 can be determined in the same run from a single biological sample. The study was published in the September 2014 issue of the Journal of Clinical Laboratory Analysis.
Related Links:
Italian National Research Council
R&D Systems
Latest Clinical Chem. News
- Blood Metabolite Test Detects Early Cognitive Decline
- AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
- Automated NfL Assay Supports Monitoring of Neurological Disorders
- Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
- New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
- CSF Biomarker Improves Diagnosis of Parkinson’s Disease and Lewy Body Dementia
- Simple Urine Home Test Kit Could Detect Early-Stage Breast Cancer
- Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
- New Tool Tracks Biomarker Changes to Predict Myeloma Progression
- New Plasma Tau Assay Improves Prediction of Alzheimer’s Progression
- First IVD Immunoassay to Detect Alzheimer’s Risk Gene Variant Receives CE Mark
- Routine Blood Markers Predict Heart Failure Risk in Prediabetes
- AI Model Enables Personalized Glucose Predictions for Type 1 Diabetes
- AI-Powered Blood Test Distinguishes Deadly Cardiac Events
- AI Sensor Detects Neurological Disorders Using Single Saliva Drop
- Blood Test Tracks Transplant Health Using Donor DNA
Channels
Molecular Diagnostics
view channel
ctDNA MRD Test Identifies Breast Cancer Patients Who May Avoid Surgery
Selecting surgery versus non-surgical management in early-stage breast cancer can be challenging for older patients, who often balance disease control with comorbidities and quality-of-life considerations.... Read more
WGS MCED Assay Demonstrates Rising Sensitivity and High Specificity
Early detection of cancer remains difficult across many tumor types, and current single‑cancer screening modalities leave significant gaps. Blood‑based, multi‑cancer assays aim to detect tumor signals... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more







